Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors

American Heart Journal

Volumn 149, Issue 1 SUPPL., 2005, Pages

  Gurm, Hitinder S ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; DESULFATOHIRUDIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; MELAGATRAN; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG TARGETING; ENZYME INHIBITION; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIA; LUNG EMBOLISM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 10944230701     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.10.022     Document Type: Article

References (90)

1. J. Hirsh Heparin N. Engl. J. Med. 324 1991 1565 1574
2. J.I. Weitz, M. Hudoba, and D. Massel Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J. Clin. Invest. 86 1990 385 391
3. Z. Xiao, and P. Theroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256
4. A. Aggarwal, B.E. Sobel, and D.J. Schneider Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention J. Thromb. Thrombolysis 13 2002 161 165
5. D.T. Eitzman, L. Chi, and L. Saggin Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4 Circulation 89 1994 1523 1529
6. P. Theroux, D. Waters, and J. Lam Reactivation of unstable angina after the discontinuation of heparin N. Engl. J. Med. 327 1992 141 145
7. M.A. Lauer, P.L. Houghtaling, and J.G. Peterson Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial Circulation 104 2001 2772 2777
8. B.H. Chong Heparin-induced thrombocytopenia J. Thromb. Haemost. 1 2003 1471 1478
9. L. Badimon, B.J. Meyer, and J.J. Badimon Thrombin in arterial thrombosis Haemostasis 24 1994 69 80
10. R. Bar-Shavit, A. Kahn, and G.D. Wilner Monocyte chemotaxis: stimulation by specific exosite region in thrombin Science 220 1983 728 731
11. R. Bar-Shavit, A. Kahn, and J.W. Fenton II Chemotactic response of monocytes to thrombin J. Cell Biol. 96 1983 282 285
12. J. Nappi The biology of thrombin in acute coronary syndromes Pharmacotherapy 22 2002 90S 96S
13. M.T. Stubbs, H. Oschkinat, and I. Mayr The interaction of thrombin with fibrinogen. A structural basis for its specificity Eur. J. Biochem. 206 1992 187 195
14. W. Bode, and M.T. Stubbs Spatial structure of thrombin as a guide to its multiple sites of interaction Semin. Thromb. Hemost. 19 1993 321 333
15. M.T. Stubbs, and W. Bode A player of many parts: the spotlight falls on thrombin's structure Thromb. Res. 69 1993 1 58
16. M.T. Stubbs, and W. Bode A model for the specificity of fibrinogen cleavage by thrombin Semin. Thromb. Hemost. 19 1993 344 351
17. M.A. Parry, J.M. Maraganore, and S.R. Stone Kinetic mechanism for the interaction of Hirulog with thrombin Biochemistry 33 1994 14807 14814
18. J.I. Witting, P. Bourdon, and D.V. Brezniak Thrombin-specific inhibition by and slow cleavage of hirulog-1 Biochem. J. 283 1992 737 743
19. S.L. Adams The medicinal leech: historical perspectives Semin. Thromb. Hemost. 15 1989 261 264
20. J. Lefkovits, and E.J. Topol Direct thrombin inhibitors in cardiovascular medicine Circulation 90 1994 1522 1536
21. G. Nowak, E. Bucha, and T. Goock Pharmacology of r-hirudin in renal impairment Thromb. Res. 66 1992 707 715
22. J.I. Weitz, and M. Crowther Direct thrombin inhibitors Thromb. Res. 106 2002 V275 V284
23. R. Vanholder, A. Camez, and N. Veys Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients Thromb. Haemost 77 1997 650 655
24. J.M. Walenga An overview of the direct thrombin inhibitor argatroban Pathophysiol. Haemost. Thromb. 32 Suppl. 3 2002 9 14
25. C.N. Berry, C. Girardot, and C. Lecoffre Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin Thromb. Haemost. 72 1994 381 386
26. C. Lunven, C. Gauffeny, and C. Lecoffre Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin Thromb. Haemost. 75 1996 154 160
27. E. Gandossi, C. Lunven, and C. Gauffeny Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors Thromb. Haemost. 80 1998 840 844
28. S.K. Swan, and M.J. Hursting The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction Pharmacotherapy 20 2000 318 329
29. R. Robson, H. White, and P. Aylward Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender Clin. Pharmacol. Ther. 71 2002 433 439
30. A.A. van den Bos, J.W. Deckers, and G.R. Heyndrickx Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty Circulation 88 1993 2058 2066
31. H.J. Rupprecht, W. Terres, and C. Ozbek Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina J. Am. Coll. Cardiol. 26 1995 1637 1642
32. P.W. Serruys, J.P. Herrman, and R. Simon A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators N. Engl. J. Med. 333 1995 757 763
33. B.E. Lewis, W.H. Matthai Jr., and M. Cohen Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Catheter. Cardiovasc. Interv. 57 2002 177 184
34. F. Cetta, L.C. Graham, and L.L. Wrona Argatroban use during pediatric interventional cardiac catheterization Catheter. Cardiovasc. Interv. 61 2004 147 149
35. K. Sakai, H. Oda, and A. Honsako Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy Catheter. Cardiovasc. Interv. 59 2003 351 354
36. T. Imanishi, M. Arita, and Y. Tomobuchi Effects of locally administered argatroban on restenosis after balloon angioplasty: experimental and clinical study Clin. Exp. Pharmacol. Physiol. 24 1997 800 806
37. T. Imanishi, M. Arita, and M. Hamada Effects of locally administration of argatroban using a hydrogel-coated balloon catheter on intimal thickening induced by balloon injury Jpn. Circ. J. 61 1997 256 262
38. J.A. Bittl, J. Strony, and J.A. Brinker Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators N. Engl. J. Med. 333 1995 764 769
39. J.A. Bittl, B.R. Chaitman, and F. Feit Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study Am. Heart J. 142 2001 952 959
40. A.M. Lincoff, N.S. Kleiman, and K. Kottke-Marchant Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am. Heart J. 143 2002 847 853
41. A.M. Lincoff, J.A. Bittl, and N.S. Kleiman Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am. J. Cardiol. 93 2004 1092 1096
42. A.M. Lincoff, J.A. Bittl, and R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
43. A.M. Lincoff, R.M. Califf, and K.M. Anderson Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators J. Am. Coll. Cardiol. 30 1997 149 156
44. D.L. Bhatt, S.P. Marso, and A.M. Lincoff Abciximab reduces mortality in diabetics following percutaneous coronary intervention J. Am. Coll. Cardiol. 35 2000 922 928
45. L. Cho, D.P. Chew, and D.J. Moliterno Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition Am. J. Cardiol. 91 2003 742 743
46. R. Wolfram, L. Leborgne, and E. Cheneau Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention Am. J. Cardiol. 92 2003 1080 1083
47. K.W. Mahaffey, B.E. Lewis, and N.M. Wildermann The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results J. Invasive Cardiol. 15 2003 611 616
48. H.S. Gurm, A.M. Lincoff, and N.S. Kleiman Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions Am. J. Cardiol. 94 2004 30 34
49. D.P. Chew, D.L. Bhatt, and W. Kimball Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials Am. J. Cardiol. 92 2003 919 923
50. N.W. Shammas, J.H. Lemke, and E.J. Dippel Bivalirudin in peripheral vascular interventions: a single center experience J. Invasive Cardiol. 15 2003 401 404
51. D.E. Allie, M.D. Lirtzman, and C.H. Wyatt Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions J. Invasive Cardiol. 15 2003 334 342
52. S. Sharma, B. Bhambi, and W. Nyitray Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure J. Cardiovasc. Pharmacol. Ther. 8 2003 9 15
53. Direct Thrombin Inhibitor Trialists' Collaborative Group Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data Lancet 359 2002 294 302
54. R. Glaser, H.C. Herrmann, and S.A. Murphy Benefit of an early invasive management strategy in women with acute coronary syndromes JAMA 288 2002 3124 3129
55. D.J. Cohen Invasive vs conservative management of acute coronary syndromes: do the data support the guidelines? JAMA 288 2002 1905 1907
56. F.J. Neumann, A. Kastrati, and G. Pogatsa-Murray Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial JAMA 290 2003 1593 1599
57. B.I. Eriksson, P. Kalebo, and S. Ekman Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement Thromb. Haemost. 72 1994 227 231
58. B.I. Eriksson, S. Ekman, and P. Kalebo Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin. CGP 39393 Lancet 347 1996 635 639
59. B.I. Eriksson, S. Ekman, and S. Lindbratt Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement J. Bone Joint Surg. Am. 79 1997 326 333
60. B.I. Eriksson, P. Wille-Jorgensen, and P. Kalebo A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement N. Engl. J. Med. 337 1997 1329 1335
61. F. Schiele, F. Lindgaerde, and H. Eriksson Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group Thromb. Haemost. 77 1997 834 838
62. J.S. Ginsberg, M.T. Nurmohamed, and M. Gent Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery Circulation 90 1994 2385 2389
63. T. Sakuragi, Y. Sakao, and K. Furukawa Successful management of acute pulmonary embolism after surgery for lung cancer Eur. J. Cardiothorac. Surg. 24 2003 580 587
64. H. Eriksson, U.G. Eriksson, and L. Frison Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT Thromb. Haemost. 81 1999 358 363
65. E. Bredberg, T.B. Andersson, and L. Frison Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions Clin. Pharmacokinet. 42 2003 765 777
66. B.I. Eriksson, D. Bergqvist, and P. Kalebo Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial Lancet 360 2002 1441 1447
67. B.I. Eriksson, G. Agnelli, and A.T. Cohen The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study J. Thromb. Haemost. 1 2003 2490 2496
68. B.I. Eriksson, G. Agnelli, and A.T. Cohen Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement Thromb. Haemost. 89 2003 288 296
69. J.A. Heit, C.W. Colwell, and C.W. Francis Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study Arch. Intern. Med. 161 2001 2215 2221
70. C.W. Francis, B.L. Davidson, and S.D. Berkowitz Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial Ann. Intern. Med. 137 2002 648 655
71. C.W. Colwell Jr., S.D. Berkowitz, and B.L. Davidson Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study J. Thromb. Haemost. 1 2003 2119 2130
72. C.W. Francis, S.D. Berkowitz, and P.C. Comp Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N. Engl. J. Med. 349 2003 1703 1712
73. H. Eriksson, K. Wahlander, and D. Gustafsson A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I J. Thromb. Haemost. 1 2003 41 47
74. J. Harenberg, J. Ingrid, and F. Tivadar Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran Isr. Med. Assoc. J. 4 2002 1003 1005
75. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
76. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
77. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
78. S.R. Steinhubl, P.B. Berger, and J.T. Mann III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
79. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators Circulation 96 1997 769 777
80. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators Lancet 353 1999 429 438
81. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group Eur. Heart J. 18 1997 1416 1425
82. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators N. Engl. J. Med. 335 1996 775 782
83. E.M. Antman Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation 94 1996 911 921
84. K.L. Neuhaus, G.P. Molhoek, and U. Zeymer Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial J. Am. Coll. Cardiol. 34 1999 966 973
85. H. White Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial Lancet 358 2001 1855 1863
86. S. Behar, H. Hod, and E. Kaplinsky Argatroban versus heparin as adjuvant therapy for thrombolysis for acute myocardial infarction: safety considerations ARGAMI-2 study Circulation 98 1 Suppl. 1998 I-453 I-454 [abstract]
87. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators Circulation 90 1994 1631 1637
88. E.M. Antman Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial Circulation 90 1994 1624 1630
89. K.L. Neuhaus, R. von Essen, and U. Tebbe Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK) Circulation 90 1994 1638 1642
90. D. Rott, S. Behar, and H. Hod Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures Am. Heart J. 141 2001 267 276